

Jaime O Herrera-CÃ¡ceres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/858042/publications.pdf>

Version: 2024-02-01

30
papers

229
citations

1307366

7
h-index

1058333

14
g-index

30
all docs

30
docs citations

30
times ranked

435
citing authors

#	ARTICLE	IF	CITATIONS
1	Smarter screening for prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 991-999.	1.2	44
2	Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management. <i>World Journal of Urology</i> , 2019, 37, 437-443.	1.2	41
3	The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity. <i>Cancer</i> , 2019, 125, 1050-1059.	2.0	28
4	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. <i>BJU International</i> , 2020, 125, 525-530.	1.3	21
5	Future developments in ureteral stents. <i>Current Opinion in Urology</i> , 2019, 29, 124-128.	0.9	19
6	The correlation between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED): results from a survey in males from Mexico City (MexiLUTS). <i>World Journal of Urology</i> , 2016, 34, 979-983.	1.2	14
7	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. <i>Canadian Urological Association Journal</i> , 2020, 14, E453-E457.	0.3	11
8	Genetic variations in toll-like receptor 4 in Mexican-Mestizo patients with intra-abdominal infection and/or pneumonia. <i>Immunology Letters</i> , 2013, 153, 41-46.	1.1	7
9	Concordance Between Two Enzyme Immunoassays for the Detection of Clostridium difficile Toxins. <i>Archives of Medical Research</i> , 2010, 41, 92-96.	1.5	6
10	Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?. <i>Cancer Medicine</i> , 2020, 9, 3287-3296.	1.3	6
11	Roles for active surveillance in renal cancer. <i>Current Opinion in Urology</i> , 2018, 28, 375-382.	0.9	5
12	Incidence and treatment of malignant tumors of the genitourinary tract in renal transplant recipients. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 874-881.	0.7	5
13	Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest, and industrial sponsorship. <i>World Journal of Urology</i> , 2020, 38, 741-746.	1.2	4
14	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. <i>Prostate</i> , 2021, 81, 286-294.	1.2	4
15	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e1-848.e7.	0.8	3
16	Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis. <i>Urology</i> , 2020, 137, 102-107.	0.5	2
17	Predictors of prostate-specific antigen testing in men aged 55 years: A cross-sectional study based on patient-reported outcomes. <i>International Journal of Urology</i> , 2020, 27, 711-718.	0.5	2
18	Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 431.e1-431.e8.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Prevalence and variables associated with an abnormal ankle-brachial index among patients with human immunodeficiency virus/acquired immunodeficiency syndrome. <i>Vascular</i> , 2018, 26, 540-546.	0.4	1
20	MPO3-02 PRIMARY ADRENAL MALIGNANCY: INSIGHTS INTO THE EPIDEMIOLOGY OF A RARE HISTOLOGICAL SUBSET. <i>Journal of Urology</i> , 2018, 199, .	0.2	1
21	Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721988280.	0.9	1
22	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. <i>European Urology Open Science</i> , 2020, 21, 1-4.	0.2	1
23	Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. <i>European Urology Focus</i> , 2020, 7, 797-806.	1.6	1
24	MP25-18 UTILITY OF ENEMAS BEFORE TRANSRECTAL PROSTATE BIOPSIES: PRELIMINARY REPORT. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
25	Sexual Function Variation in Liver Transplant Patients. <i>Gastroenterology</i> , 2017, 152, S1130.	0.6	0
26	MP49-08 IS THE HYBRID ILEO-URETERIC ANASTOMOSIS A BETTER ALTERNATIVE THAN THE BRICKER OR WALLACE ANASTOMOSIS FOR ILEAL CONDUIT URINARY DIVERSION?. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
27	MPO5-16 SALVAGE PROSTATECTOMY AFTER FOCAL THERAPY “ SINGLE CENTRE EXPERIENCE. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
28	Patient-centered care can be improved by joint meetings between cancer patient group leaders and health care providers. <i>Patient Education and Counseling</i> , 2022, 105, 786-787.	1.0	0
29	Functional and metabolic complications of androgen deprivation therapy. <i>World Journal of Clinical Urology</i> , 2014, 3, 227.	0.0	0
30	Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	0